Mice with a germ line p53 mutation (p53 Ala135Val/wt ) display increased susceptibility to lung, skin, and colon carcinogenesis. Here, we show that p53
Introduction
Ovarian cancer is the fifth leading cause of cancer death in women, and is the leading cause of death from gynecologic malignancy. It has been estimated that there were 20,180 new cases and 15,310 ovary cancer deaths in the United States during 2006 (1) . Ovarian cancer is classified into three major groups based on their distinct histologic origins. The most common ovarian cancers are epithelial cancers, which originate from the ovarian surface lining. This type accounts for f90% of all ovarian cancers. The second type of ovarian cancers are germ cell tumors, which account for f5% of all ovarian cancers. The third type of ovarian cancers are the specialized stromal cell cancers. Although it accounts for only <5% of all ovarian cancers, it is a highly aggressive form of cancer.
Ovarian cancer is idiopathic, although it is associated with multiple genetic alterations. Dysfunction of p53 is one of the most common genetic alterations found in cancer, occurring in up to 50% of all human malignancies (2) . The p53 tumor suppressor protein is a central regulator of cell growth, DNA damage repair, and apoptosis (3) . It directly activates the expression of a substantial number of genes important for cell cycle regulation and apoptosis (4) . Although, p53 gene alterations are rare events in benign ovarian tumors, previous studies have shown that p53 is mutated in f50% of late stage (stage III/IV) ovarian cancers (5) . Furthermore, mutated p53 genes with resultant overexpression of p53 proteins occurs frequently in ovarian sarcomas (6) .
We reported that p53 Ala135Val/wt mice are highly susceptible to carcinogen-induced tumors including lung (7) and skin tumors (8) . However, the role of germ line p53 mutation in mouse ovarian carcinogenesis has not been examined previously in this rodent model. For this reason, we have carried out an ovarian carcinogenesis study with 7,12-dimethylbenz(a)anthracene (DMBA). Here, we report that p53
Ala135Val/wt mice display significantly increased susceptibility to DMBAinduced ovarian tumor carcinogenesis. Alterations of several cellular processes, including cell cycle arrest, apoptosis, and Wnt pathways, may mediate enhanced DMBA-induced ovarian tumor carcinogenesis in p53
Ala135Val/wt mice.
Results and Discussion
Three months post-DMBA treatment, p53 Ala135Val/wt mice had developed significantly more advanced tumor phenotypes (larger ovarian tumors) compared with their wild-type littermates. The survival rate of p53 wt/wt mice was significantly higher than p53
Ala135Val/wt mice ( Fig. 1) . Most of the p53 Ala135Val/wt mice were dead or moribund before the end of the experiment due to advanced ovarian tumors. On an average of 17 weeks post-DMBA treatment, 100% of the p53 tumors. The tumors presented as large masses with reddish color from the ovary on the left side, and aggressively invaded surrounding organs including the spleen, intestine, kidney, and uterus. The control ovaries (right side) looked normal at f2 mm in diameter. Histologically, 50% (4 of 8) of the ovarian tumors in p53 wt/wt mice and f23% (3 of 13) of the ovarian tumors in p53
Ala135Val/wt mice are adenocarcinomas (Fig. 2F, a) . Some of the adenocarcinomas consisted of areas with some degree of sarcoma features. The remaining tumors displayed typical features of ovarian sarcomas (Fig. 2F, b) . Approximately 40% of the tumors had invaded into the surrounding organs, including the pancreas, spleen, uterus, and kidney. For comparison, the normal structure of the ovary was stained and are shown in Fig. 2 (A, B, and C), and the ovarian tumors in (D, E, and F) at 40Â, 100Â, and 400Â magnifications, respectively. Adenocarcinoma cells (Fig. 2F , a) are arranged with glandular structures in back-to-back nests which are separated by lumina. The nuclear/cytoplasmic ratio is high in these cells. The nuclei show obvious pleomorphisms, granular chromatin, and large plump nuclei with prominent nucleoli. Sarcoma cells (Fig. 2F, b) are arranged in bundles and streams and are in an overall spindle shape. Their nuclei are elongated or oval and variable in size. Although the nuclei contained coarse to clumped chromatin and the occasional prominent nucleoli, the cytoplasm was eosinophilic and fibrillar. There is also no significant difference in the mitotic index between mutant p53 mice and wild-type p53 mice. The average mitotic index was 2 F 0.875 per field under a 400Â magnification. Al a135Val/w t transgenic mice. Both p53
Ala135Val/wt transgenic mice and their wild-type littermates were monitored for the development of ovarian tumors. Moribund animals were terminated, and the tissues were collected for histopathologic and molecular analysis. Genotypes: E, wild-type; n, p53
Ala135Val/wt . Ala135Val/wt mice are adenocarcinomas. Some of the adenocarcinomas consisted of areas with some degree of sarcoma features. The remaining tumors displayed typical features of ovarian sarcomas. Adenocarcinoma cells are arranged with glandular structures in back-to-back nests which are separated by lumina. The nuclear/cytoplasmic ratio is high in these cells. The nucleus shows obvious pleomorphism, granular chromatin, and large plump nuclei with prominent nucleoli. Sarcoma cells are arranged in bundles and streams and are in an overall spindle shape. Their nuclei are elongated or oval and variable in size. Although the nuclei contained coarse to clumped chromatin and the occasional prominent nucleoli, the cytoplasm was eosinophilic and fibrillar. A normal mouse ovary [magnification, Â40 (A), Â100 (B), and Â400 (C)]. DMBA-induced ovarian tumors [magnification, Â40 (D), Â100 (E), and Â400 (F; a, adenocarcinoma; b, sarcoma)].
No tumors were found in either p53
wt/wt or p53
Ala135Val/wt DMSO control mice. There were no statistically significant differences between the body weights of any of the groups treated with DMBA as compared with the controls. However, the majority of p53 Ala135Val/wt mice were terminated before the end of the experiment due to the abundance of tumors. The survival data was shown in Fig. 1 . Our data clearly showed that p53 Ala135Val/wt mice have an increased susceptibility to DMBAinduced ovarian tumors. Because spontaneous ovarian tumors are rare in the mouse, DMBA-induced ovarian tumors in p53
Ala135Val/wt mice has become a potential model for human ovarian tumors to aid our studies on ovarian cancer chemoprevention, early detection, and therapy.
The RAS mitogen-activated protein kinase signal transduction pathway has been shown to interact with the ARF-p53 pathway in the processes of cell transformation and carcinogenesis. We did K-ras2 mutation analyses on a total of 20 tumors (10 from p53
Ala135Val/wt mice and 10 from p53 wt/wt mice). The direct sequencing analysis revealed that 30% of the tumors (6 out of 20) harbored mutations in codons 13 and 61 (Supplementary Table S1 ). There was no mutation identified in codon 12. Also, there was no significant difference in the incidence and types of mutations between tumors from p53 wt/wt and p53 Ala135Val/wt mice (Supplementary Table S1) . Microarray analyses were then done on normal and tumor tissues from ovaries treated with DMBA. Differential gene expression was based on p53 genotype status and ovarian tumor phenotype (z2.0-fold change, P V 0.05). A total of 20 samples (five from each group, normal and tumor samples from both p53 wt/wt and p53 Ala135Val/wt mice) were examined with microarray analysis. In order to see the genetic effect of mutated p53 on gene expression in mouse ovary tissues, we compared the expression profiles of normal ovaries of p53
Ala135Val/wt mice to those of p53 wt/wt mice. We identified 30 genes with at least 2.5-fold change in expression (P V 0.05; Table 1A ). Of these, 15 were underexpressed and 15 were overexpressed in p53
Ala135Val/wt mice. The overexpressed genes include transformation-related protein 53, early growth response 2, peroxisome proliferator-activated receptor binding protein, arginine vasopressin receptor 2, defensin-related cryptdin 6, and phosphoinositide-3-kinase adaptor protein 1. Underexpressed genes include ELAV-like 3, carbonic anhydrase 1, islet amyloid polypeptide, integrin h7, prolactin-induced protein ubiquitin C, and forkhead box N1.
Interestingly, the elevated expression levels of 12 genes seen in the p53
Ala135Val/wt normal samples were also maintained at the same or even higher levels in the p53
Ala135Val/wt tumors (Table 1B) . Similarly, the same pattern was seen with two down-regulated genes, IFN-activated gene 205 and ELAV (embryonic lethal, abnormal vision, Drosophila)-like 3 (Table  1B) . We have identified a large set of genes which are modulated during tumorigenesis regardless of p53 status. Only the genes with >5-fold change (P < 0.05) are listed in Table 2 . These genes play important roles in several critical biological functions, including apoptosis (Bak1, Pawe, and Tnfrsf19), tumorigenesis (Fosl1, Glipr1, Plk1, etc.), cell cycle regulation (Cdkn2a, Cdc25c, Ccnb1, etc.), cell growth and differentiation (TGFa, EGFl6, FGFr2, etc.), signal transduction (Rgs16, Racgap1, Prkca, etc.), and transcriptional regulation (Etv4, Tcfec, Gata4, etc.), as well as the oncogene Myb and tumor suppressor gene Wt1. In Table 2 , genes altered only in p53 wt/wt tumors include genes related to cancer (Ris2, Srcasm, and Sdccag33l), cell cycle regulation (cdc6, Bub1, Bub1b, Ccnb2, Nusap1, and Trp63), cell growth and differentiation (Edg7 and Mal), oncogenesis (Rin1, Src, Brca1, Ect2, and Erbb3), signal transduction (Rad23b, Rgs2, Stard5, Gpr56, Rab3d, Rerg, Mark1, Rab25, and Frzb), and transcriptional regulation (Rcor1). In Table 2 , genes altered only in p53 Ala135Val/wt tumors include genes involved in apoptosis (Perp and Bcl2l10), a cancer-related gene (Gfra1), cell growth and differentiation (Csf1 and FGFr3), signal transduction (Gpr85, Arhgdib, Rad51ap1, Gpr155, and Gnai1), and transcriptional regulation (Gata6 and Tcfcp2l2).
Genes that were altered only in p53 Ala135Val/wt tumors as compared with p53 wt/wt tumors and only in p53 val135/wt normal ovary as compared with p53 wt/wt normal ovary (Table 1A ; Fig. 3A ) are listed in Table 3 . The tumor-related genes are involved in apoptosis (Bcl7a and Biklk), tumorigenesis (Xpa, Gfra1, Bcas3, Mas1, Hrasls, and Vav2), cell cycle regulation (Ccna1, Cwf19l1, and Cdkn2a), cell growth and differentiation (IGFals, Neurod1, and FGF6), signal transduction (Gpr74, Rab3c, Wnt8a, Mark1, Gpr73, Fzd5, and Rhpn2), and transcriptional regulation (Pou6f1, Pou4f3, Pou2f1 , and Tcfcp2l2). We used GenMAPP to illustrate all the signaling pathways containing differentially expressed genes associated with p53 status in ovarian tumorigenesis. Several cellular pathways showed alterations in ovarian tumors (yellow represents the changes in wild-type tumors and blue represents the changes in p53
Ala135Val/wt tumors with their corresponding normal as control). The altered pathways include ones that regulate apoptosis ( Supplementary Fig. S1 ), cell cycle regulation ( Supplementary Fig. S2 ), and Wnt ( Supplementary  Fig. S3 ). These indicated that reduction of apoptotic activity and altered cell cycle regulations contribute, at least in part, to the observed increase in ovarian malignancy predisposition in mice treated with DMBA. It is important to note that the majority of cells in the normal ovary are of the stromal subtype, and that some of the differences in the expression profiles between normal ovaries and adenocarcinomas might be due to the enrichment of the epithelial cells in adenocarcinomas.
Among the genes with altered expression, we selected 12 for real-time PCR validation using qPCR analysis (Bio-Rad Laboratories) on the Bio-Rad iCycler iQ Real Time PCR Instrument. Mouse glyceraldehyde-3-phosphate dehydrogenase was used as the reference control for normalization of template. Ten of the 12 genes were correctly confirmed (Fig. 3B) ; the validating rate was 86%. Figure 3B shows 10 of the confirmed genes (two no-change genes were not shown). In a comparison of p53 wt/wt tumor to p53 wt/wt normal, Cdh1, Bak1, Apaf1, Cdc20, CyclinB2, cdc25C, and Bub1 were confirmed. Casp7 was not confirmed. In a comparison of p53
Ala135Val/wt tumor to p53 Ala135Val/wt normal, Cdh1, CyclinA2, and cdc25c were confirmed. Bad was not confirmed.
The ovary is an organ formed of many different cell types. Tumors that arise from this organ include epithelial ovarian carcinomas, germ cell tumors, and stroma tumors. There are several transgenic mouse models established for the ovarian tumor. In one mouse model, re-introduction of ovarian cells exhibiting loss of p53 in combination with two activated oncogenes (c-Myc, K-Ras, or Akt) to the ovarian bursa results in the development of ovarian carcinomas (9) . In another model, 97% of the animals developed spontaneous ovarian carcinomas in conditionally inactivated p53 and Rb mice (10) . Also, Connolly et al. reported that TgMISIIR-TAg transgenic mice developed bilateral ovarian carcinomas accompanied by ascites and peritoneal implants (11) . These tumors have all been characterized histopathologically as ovarian adenocarcinoma derived from the ovarian surface epithelial cells. There have been reports that radiation induces ovarian granulosum cell tumors (12). Chen et al. reported that surgical transplantation of ovaries from p53 homozygous knockout mice into histocompatible wild-type female hosts induces angiosarcoma rather than epithelial malignancy 1 year posttransplantation (13) .
Here, we report the induction of ovarian tumors by DMBA in p53
Ala135Val/wt transgenic mice and the identification of the potential molecular mechanisms involved. The ovarian tumors induced by DMBA treatment in p53
Ala135Val/wt mice were diagnosed as either adenocarcinomas or sarcomas. Nearly half of the tumors invaded into its surrounding organs. Although we observed 100% and 80% tumor frequencies in p53
Ala135Val/wt and p53 wt/wt mice, respectively (data not shown), the p53
Ala135Val/wt mice developed more aggressive tumors with a shorter survival time. At 25 weeks post-DMBA treatment, 100% of the p53 Ala135Val/wt mice had died, whereas only 50% of the p53 wt/wt mice had died. Our study has established a unique animal model for further investigation of this disease.
We previously reported that similar treatment with DMBA sutures in Wistar Furth rats resulted in the development of primarily ovarian adenocarcinomas and ovarian granulosum cell tumors (14) . Similarly, we observed that 50% of the ovarian tumors were adenocarcinomas and the remaining 50% were ovarian sarcomas in p53 wt/wt mice. Approximately 23% of the ovarian tumors were adenocarcinomas and 77% were sarcomas in p53
Ala135Val/wt mice. Thus, p53 Ala135Val/wt mice seem to be a model for human ovarian tumors because alteration of the p53 gene is the most frequently identified genetic change in ovarian carcinomas, affecting >50% of advanced and early stage carcinomas (5, 6) . The role of the p53 tumor suppressor gene in malignancy has been intensely investigated in the past. It has been shown that mutation of the p53 is the most frequently identified genetic alteration in ovarian tumors as it affects >50% of advanced carcinomas and ovarian sarcomas (5). In the current studies, we show that p53 is an important factor in ovarian carcinogenesis induced by DMBA: the germ line mutation of p53 leads to an increased response of ovarian cells to DMBA treatment, possibly, through impairment of the ability to control cell cycle regulation and apoptosis.
Through microarray analysis, we identified clusters of genes which might hold the keys to explaining the mechanisms underlying (a) DMBA-induced ovarian carcinogenesis and (b) aggressive behavior of the ovarian tumors in p53
Ala135Val/wt mice. One cluster of genes was altered in the normal ovary of p53 Ala135Val/wt mice as compared with the levels in the normal ovary of p53 wt/wt mice (Supplementary Table S1 ). Because the only difference that existed in the normal tissues was the p53 germ line mutation, we can predict that altered expression could be the consequence of this mutation. Interestingly, the expression levels of some altered expressions (including Trp53, Msh5, Egr2, Olr1, Ifi205, and Elavl3) were maintained at a similar level in ovarian tumors of p53 Ala135Val/wt mice as well (Table 1) . One such gene is MSH5 (MutS homologue 5), which is a member of the DNA mismatch repair protein family which play important roles in maintaining accurate genetic transmission in both mitotic and meiotic processes (15, 16) . In our case, Msh5 overexpression might not contribute to ovarian tumorigenesis. Egr1 is a member of the immediate-early gene family. It is involved in the regulation of cell growth and differentiation in response to signals, such as mitogens, growth factors, and stress stimuli (17, 18) . Egr1 could act as both a tumor suppressor and a tumor promoter in a tissue-specific manner. In most human tumors, such as breast cancer, fibrosarcoma, and glioblastoma, Egr1 is described as a tumor suppressor gene (19) . One of the mechanisms of suppression has been NOTE: Genes were differentially expressed >5.0-fold and P < 0.05; real-time PCR -confirmed (values in boldface, P < 0.05). N, normal ovarian tissue; T, ovarian tumor. implicated in the regulation of p53 leading to apoptosis (20) . However, the tumor-suppressing role seems to be tissuespecific because recent studies implicated the tumor growthpromoting role of Egr1 in prostate cancer progression (21) . Higher levels of Egr1 were found in prostate cancer (22) . Egr1 is growth-promoting for vascular smooth muscle cells and for rat kidney tumor cells (23, 24) . Our results suggest that the Egr1 gene acts as tumor promoters in DMBA-induced ovarian tumorigenesis as their expression levels were increased in tumors. However, it is more likely due to the increased p53 Ala135Val/wt expression in the tissues. This hypothesis is supported by recent observations that p53 is a direct target of Egr1 as the p53 promoter contains two Egr1-binding sites (25) .
We identified two clusters (A and B) of genes with altered expression only in p53
Ala135Val/wt ovarian tumors as compared with p53
Ala135Val/wt normal ovary. No expression changes were identified in these genes in p53 wt/wt ovarian tumors compared with p53 wt/wt normal ovary (Fig. 3) . Cluster A includes overexpressed genes, and cluster B contained underexpressed genes. From the past, cumulative studies have shown that p53 mutations are the most common genetic alterations in advanced ovarian cancer, implicating that p53 mutations play important roles in human ovarian cancer progression. The fact that the expression levels of these genes were altered in p53
Ala135Val/wt tumors but not in p53 wt/wt tumors suggests the possibility that these genes have a role in the more aggressive behavior of p53 Ala135Val/wt ovarian tumors. One of the overexpressed genes is microtubule-associated cytoplasmic dynein light intermediate chain 1. Microtubules play a central role in coordinating various cellular functions, including cell shape, motility, signal transduction and intracellular organelle transport during interphase, and the formation of mitotic spindles and the cytokinesis bridge during cell division. Evidence also indicates that microtubuleassociated molecules may have a role in cancer cell proliferation and cell survival. In general, dynein is implicated in many important processes within eukaryotic cells during interphase (26) . During cell division, dynein functions in the formation, alignment, and maintenance of mitotic spindles, as well as the movement and positioning of chromosomes (27) . The cytoplasmic dynein complex is composed of four subunit classes: the heavy, intermediate, light-intermediate, and light chains. Dynein light chain 1 (DLC1) interacts with BimL, a Bcl-2 family member (28) and Pak1 (29) . Pak1 is the p21-activated kinase 1, which could form a complex with DLC1 and BimL to phosphorylate both proteins. Phosphorylated BimL is then prevented from interacting with and inactivating Bcl-2. The interaction of DLC1-Pak1-BimL promotes cell survival by blocking BimL's apoptotic functions. Overexpression of DLC1 is detected in human breast tumors and breast cancer cells, and up-regulation of DLC1 exists with overexpressed Pak1 in 50% of breast cancers (29) . Deregulation of Pak1 expression is reported in breast and ovarian cancers (30) . Although upregulation of dynein is p53 dependent, we saw overexpressed Pak1 in ovarian tumors regardless of p53 status. BimL is not found on the array. The p53 performs its tumor suppressor function by regulating transcription (3). In order for it to act, translocation of p53 from the cytoplasm into the nucleus is required, and this transportation is facilitated by cytoplasmic dynein along microtubule tracks (31) . Mutant p53 protein in p53
Ala135Val/wt mice is increased dramatically. We can speculate that the nuclear transportation of mutant p53 is facilitated by the elevated dynein light intermediate chain 1. It is a very well established fact that p53 mutation is a common event in human tumors. Approximately 50% of ovarian adenocarcinomas (1, 5) have mutants in the p53 gene. We can safely predict that the remaining f50% of the tumors must retain the wild-type p53 gene. The question that needs to be answered is why the wild-type p53 retained in these tumors is unable to perform its function to suppress tumor formation. Of course, p53 is not the only tumor suppressor gene to have been identified, and other tumor suppressors might well be involved in the development of cancers whose p53 remains unaltered. Previous studies have shown that p53 is mutated in ovarian malignancies with f50% in stage III/IV, f15% in stage I/II ovarian adenocarcinomas (1, 5) , and in f50% of ovarian sarcomas (7) . So how do the remaining ovarian tumors tolerate wild-type p53 and overcome the tumor suppression that wild-type p53 provides? Activation of oncogenes and/or inactivation of other tumor suppressor genes are ways to bypass the requirement for p53 mutation. In Table 2 , there is a set of ''p53-bypassing'' genes as their expression levels were only altered in p53 wt/wt tumors, not in p53 Ala135Val/wt tumors. Altered expression of these genes could contribute to ovarian tumorigenesis in p53 wt/wt mice. These genes primarily fall into three functional groups, overexpressed oncogene/tumor suppressor genes (Rin1, Src, Brca1, and Ect2), overexpressed cell cycle regulatory genes (Cdc6, Bub1, Bub1b, Ccnb2, and Nusap1), and underexpressed signal transduction regulatory genes (Rgs2, Stard5, Gpr56, Rab3d, Rerg, Mark1, Rab25, and Frzb). Although Brca1 is defined as a tumor suppressor gene, it is overexpressed in DMBA-induced mouse ovarian tumors. This overexpressed Brca1 could be a mutant form. Interestingly, a member of the p53 family, Trp63, is significantly down-regulated in the p53 wt/wt tumors. This down-regulation of Trp63 was not observed in p53
Ala135Val/wt tumors. On the other hand, there are some genes which are only altered in p53
Ala135Val/wt tumors, indicating that these genes function independently of p53. One set of these genes is signal transduction -related, including the genes Gpr85, Arhgdib, Rad51ap1, Gpr155, and Gnai1. The second set of genes, which included Perp and Bcl 2110, are apoptosis-related.
Another common genetic alteration in ovarian cancer are point mutations in the K-ras2 gene. Mutated K-ras2 product is involved in the control of growth-stimulatory and cell death pathways. Previous studies have shown that activation of K-ras2 by a point mutation in codon 12/13 was frequently detected in ovarian tumors (32) , with a mutation frequency of 41% to 60%, suggesting the involvement of K-ras2 in this type of tumor. DMBA-induced mammary tumors in rodents harbored mutations. The majority of the mutations were purine (AG) to pyrimidine (CT) transversions (12/19) on the nontranscribed strand, which is likely to be due to depurination created by DMBA adduct formation on the nontranscribed strand (33) . In the DMBA-induced ovarian tumors, base substitutions at A or G accounted for 95% of all the point mutations. The predominance of purine (A or G) mutations is consistent with the fact that DMBA adduct formation preferentially occurs on dA and dG, leading to depurination (34) . In our study, we analyzed point mutations in K-ras2 and found that mutation occurred in codons 13 and 61 with 40% (4 of 10) and 20% (2 of 10) of mutation frequency in ovarian sarcomas of p53 wt/wt and p53
Ala135Val/wt mice, respectively (Supplementary Table S1 ). The pattern of mutations are demonstrating the important role of K-ras2 during DMBA-induced ovarian carcinogenesis, and it is independent of histopathologic types. In this study, we have successfully used the classical carcinogenesis approach of ovarian tumor induction (35) in p53 transgenic mice. These mice not only have shortened tumor latencies but also closely resemble a subset of human ovarian tumors containing a p53 mutation. Although the general idea that p53 val135 would enhance carcinogen-induced cancer is itself not new, the observation that direct application of a chemical carcinogen to ovaries consistently induced non -granulosa cellrelated ovarian carcinomas in mice as well as the finding of synergistic interactions of the carcinogen and p53 in ovarian tumor progression are new and have not been reported previously. Although this may be expected, the end results are by no means certain because we have seen that the presence of p53 val135 in several organ sites failed to enhance carcinogeninduced tumorigenesis. 5 We believe that we have succeeded in generating a potential mouse model for the development of ovarian carcinogenesis in mice.
Finally, we begin to address the mechanism of ovarian carcinogenesis by conducting a series of microarray experiments. We have presented altered gene expression profiles that showed the gene expression differences between normal ovarian tissues from p53
Ala135Val/wt mice and those from p53 wt/wt mice (Tables 1 and 2 ). Furthermore, we showed the gene expression differences of ovarian tumors versus normal ovarian tissues, dependent or independent of p53 mutant status (Table 2) , as well as the gene expression differences between ovarian tumors of p53
Ala135Val/wt mice and those from p53 wt/wt mice ( Table 3) . We also attempted to make a biological connection in terms of the genes altered in this model system compared with the genes that are typically known to be involved in human ovarian cancer. Specifically, we compared gene expression profiles from the National Center for Biotechnology Information data set GSE6008 with 99 human individual ovarian tumors (37 endometrioid, 41 serous, 13 mucinous, and 8 clear cell carcinomas) and 4 individual normal ovary samples with our mouse array data. We found 42 genes in human ovarian tumors that had similar changes seen in mouse ovarian tumors ( Table 2 ). The p53 is a central regulator of cell growth, DNA damage repair, and apoptosis (3). The p53 directly activates the expression of a substantial number of genes important for cell cycle regulation and apoptosis (4). These two pathways, apoptosis and cell cycle, are heavily involved in DMBA-induced mouse ovarian tumorigenesis, regardless of p53 mutational status. These two mechanisms also branch out to the Wnt pathway. We believe that the results represent a starting point for follow-up in-depth molecular analyses. Some of the genes are currently further investigated in our laboratory. In light of the recent emphasis on the problems of ovarian cancer in humans, we believe that some aspects of this article, especially those related to the roles of both chemical carcinogen and the p53 mutation in the ovarian tumorigenic process, are novel and important.
Materials and Methods

Animal Bioassays
To conduct the animal bioassays, 6-week-old female mice on A/J background were grouped based on their p53 genotype, p53
Ala135Val/wt and their wild-type littermates (p53 wt/wt ). These mice were produced by backcrossing UL53-3 mice to A/J strain mice for more than 10 times. Based on an early publication (35) , DMBA was heated to its melting point (f124jC) in a chemical fume hood. Sterile 6-0 silks (2 cm in length beyond the attached needle) were immersed in the melted DMBA or in DMSO (as control), and dried before use. Surgical implantation on the ovary was done on 6-week-old mice. Anesthesia was induced with ketamine (90 mg/kg)/acepromazine (2 mg/kg) intraperitoneally. Supplemental buprenex (0.01 mg/kg) was given subcutaneously to every mouse before surgery. The lower back was shaved and swabbed with Nolvasan followed by 70% ethanol. A 2 cm dorsal incision was made to open the retroperitoneal cavity and to expose the left ovary. Using a sterile needle, a 1-cm length of 6-0 silk, impregnated with either DMBA or DMSO, was implanted into the left ovary and secured with one knot. The dorsum was closed in two layers with sutures and wound clips. All animals were observed daily for clinical signs of illness for the first 2 weeks postsurgery and twice a week thereafter. Three months after surgery, 50% of the mice from the p53 Ala135Val/wt group and a few mice from the p53 wt/wt group showed obvious tumors which could be easily palpated through the enlarged abdominal or dorsal wall. Mice, either moribund or with dramatically enlarged abdomens, were euthanized by CO 2 asphyxiation. Gross necropsy was done: all organs including the ovary, uterus, colon, intestine, lung, liver, and kidney were examined for tumors. During the tumor dissection, first of all, the implanted suture was located. Then, the surrounding tissue was collected, a representative portion of the ovarian tumors was snap-frozen in liquid nitrogen for molecular biological study and part was fixed in buffered formalin for histopathologic examination. The right side normal ovary was also removed. Tissue sections (4 Am) were stained with H&E for histopathologic evaluation according to existing human and mouse ovarian cancer classifications (36) . Fishers exact test was used to determine the difference in incidence between p53
Ala135Val/wt (n = 40) and p53 wt/wt mice (n = 35).
Gene Expression Analysis
Microarray analysis was then done on normal and tumor tissues from ovaries treated with DMBA. Total RNAs from four paired adenocarcinomas [ovarian tumor (left side) and normal ovary (right side)], were isolated by Trizol (Invitrogen) and purified with RNeasy Mini Kit and RNase-free DNase Set (QIAGEN) according to the manufacturer's protocols. In vitro transcription-based RNA amplification was then done and cDNA was synthesized using a Superscript cDNA Synthesis Kit (Invitrogen). The cDNA was cleaned using phase-lock gels (Fisher Scientific). Biotin-labeled cRNA was transcribed in vitro from cDNA using a BioArray HighYield RNA Transcript Labeling Kit (ENZO Biochem). The labeled cRNA was applied to the Affymetrix Moe430Av2 GeneChips (Affymetrix) according to the manufacturer's recommendations. Array normalization and gene expression estimates were obtained using Affymetrix Microarray Suite 5.0 software. Differential expression was determined on the combined basis of statistical testing using t tests and fold changes. A cutoff of P V 0.05 and a fold change of z2 is called positive for differential expression. For the selected genes, expression indices were transformed across samples to an N (0, 1) distribution using a standard statistical Z-transform. These values were input to the GeneCluster program of Eisen et al. (37) and genes were clustered using average linkage and correlation dissimilarities. Pathways of interest, such as cell cycle, apoptosis, mitogen-activated protein kinase, and G protein, were evaluated for differential regulation using the visualization tool GenMAPP at the University of California, San Francisco (38) . 6 We imported our results into the program and used GenMAPP to illustrate the pathways containing differentially expressed genes. Differential gene expression was based on p53 genotype status and ovarian tumor phenotype (P V 0.05, z2.0-fold change). A total of 20 samples (5 samples from each group, normal and tumor from both the p53 wt/wt and p53 Ala135Val/wt ) were examined with microarray analysis.
Real-time PCR
Selected genes were validated by real-time PCR using qPCR analysis (Bio-Rad Laboratories) on the Bio-Rad iCycler iQ Real Time PCR Instrument. Mouse glyceraldehyde-3-phosphate dehydrogenase was used as the reference control for normalization of template. RNAs from four individual ovarian tumors of p53 wt/wt and p53 Ala135Val/wt were tested with four individual normal ovary RNAs as normal controls. Each sample was run in duplicate for both tested genes and for mouse glyceraldehyde-3-phosphate dehydrogenase. The amplifications were carried out by a hot-start at 95jC for 2 min, followed by 40 cycles of 95jC for 15 s and 58jC for 45 s. The primers (5 ¶ to 3 ¶) used for real-time PCR confirmation on gene expression in ovarian tumors are available upon request.
Detection of Point Mutations in the K-ras2 Gene
The RAS mitogen-activated protein kinase signal transduction pathway has been shown to interact with the ARFp53 pathway in the processes of cell transformation and carcinogenesis. Activation of K-ras2 by point mutation in codon 12 or 13 was frequently detected in ovarian mucinous tumors (32) . In our study, we did K-ras2 mutation analysis on a total of 20 tumors (10 from p53
Ala135Val/wt mice and 10 from p53 wt/wt mice). Tumors used were ovarian adenocarcinomas either from p53 wt/wt (5 of 10) or p53 Ala135Val/wt mice (4 of 20), respectively. The rest of the tumors (5 of 10 from p53 wt/wt mice; 15 of 20 from p53
Ala135Val/wt mice) were adenocarcinomas mixed with sarcoma or sarcomas. PCR amplification and direct DNA sequencing analysis were used to identify the mutations in the K-ras2 gene. Briefly, DNA was isolated from ovarian tumors using TRIzol reagent (Invitrogen). Sequences of PCR primers for K-ras2 exons 1 (contains codons 12 and 13) and 2 (contains codon 61) were described previously (39) . A 50 AL reaction mixture containing 100 ng of genomic DNA, 10 mmol/L of Tris-HCl (pH 8.5), 50 mmol/L of KCl, 2.5 mmol/L of MgCl 2 , 100 Amol/L of each deoxyribonucleoside triphosphate (dATP, dCTP, dGTP, dTTP), 1.0 unit of Taq DNA polymerase (Promega), and 40 pmol of each primer were overlaid with sterile mineral oil and subjected to 35 cycles of PCR amplification. Each cycle consisted of 1 min each at 94jC, 52jC, and 72jC. The mutations were analyzed with an ABI PRISM 3700 DNA analyzer (PE Applied Biosystems).
